Live
- Collector Inspires Students to Excel Through Discipline, Hard Work, and Smart Work
- District Collector Directs Officials to Expedite Paddy Procurement Process
- SP T. Srinivas Rao Inaugurates State-of-the-Art Volleyball Court for Police Personnel in Jogulamba Gadwal
- Geeta Jayanti Celebrations Organized at Maldakal Thimmappa Swamy Temple
- Indiramma Housing Scheme Survey Reviewed by District Collector
- Government Committed to Resolving ASHA Workers' Issues: Minister Damodar Raja Narasimha
- 'Refrain from interfering in municipal polls': Union Minister Ravneet Bittu tells Punjab officials
- SC grants anticipatory bail to accused in POCSO case
- Rising Rajasthan Summit to return in 2026, says CM Sharma
- Kerala HC issues contempt notice to official over elephant regulation violations
Private equity firm Advent International to acquire majority stake in ZCL Chemicals
Private equity firm Advent International to acquire majority stake in ZCL Chemicals
Private equity fund Advent International on February 8 announced that it has signed a definitive agreement to acquire a majority stake in ZCL Chemicals, formerly known as Zandu Chemicals.
Private equity fund Advent International on February 8 announced that it has signed a definitive agreement to acquire a majority stake in ZCL Chemicals, formerly known as Zandu Chemicals. The transaction represents the third deal in the domestic pharma segment by Advent which has earlier acquired Hyderabad based RA Chem and Bharat Serums and Vaccines.
With this transaction, Morgan Stanley Private Equity Asia, a private equity platform that previously managed a minority investment in ZCL, will exit its investment, the announcement said. The financial terms of the deal were not disclosed.
"ZCL will be our third pharmaceuticals investment in India and the second in the API space. ZCL is a high-growth business, led by a capable management team, which will further fortify our presence in the API market, a key sub-sector focus of ours," said Shweta Jalan, a Managing Director and Head of India at Advent International, India.
"We are impressed with ZCL's differentiated product portfolio, a strong pipeline and its high focus on quality and compliance. The acquisition of ZCL helps us get closer to our goal of creating a top five merchant API platform in India," said Pankaj Patwari, Director, Advent International India.
ZCL operates in the segments of specialty active pharmaceutical ingredients (APIs) and advanced intermediates. It's a highly specialised approach focuses on niche therapeutic areas, underpinned by complex chemistry, supported by a state-of-the-art U.S. Food and Drug Administration (FDA) approved facility, along with strong research & development capabilities.
The firm is developing a strong pipeline of high potential products that are expected to drive the next phase of its growth.
Advent has been investing in India since 2007. In this time, it has deployed over $1.7 billion in 12 companies with headquarters or operations in the country. The PE fund has significant experience in the healthcare industry globally. In the past 30 years, the firm has invested or committed over $9.6 billion in 48 companies in the sector, including over 20 businesses involved in pharmaceutical R&D, production, and distribution.
